摘要
目的探讨利培酮联合氯氮平治疗难治性精神分裂症的临床疗效及安全性。方法将68例难治性精神分裂症患者随机分为两组，每组34例，研究组口服利培酮联合氯氮平治疗，对照组单用氯氮平治疗，观察8周。于治疗前及治疗第2周、4周、8周末采用阳性与阴性症状量表评定临床疗效、副反应量表评定不良反应。结果两组治疗第2周末起阳性与阴性症状量表评分均较治疗前有显著下降（P〈0．05），同期两组间比较均无显著性差异（P〉0．05）；治疗8周末，研究组有效率为61．76％，对照组为58．82％；两组无显著性差异（P〉0．05）。研究组不良反应发生率为32．35％，对照组为58．82％，研究组显著低于对照组（P〈0．05）；研究组主要表现为静坐不能、震颤、体重增加；对照组主要表现为流涎、心电图异常、肝功能异常、白细胞减少、嗜睡、头昏、体重增加等。结论利培酮联合氯氮平治疗难治性精神分裂症疗效显著，安全性高，依从性好。
Objective To explore the efficacy and safety of resperidone combined with clozapine in the treatment of treatment-resistant schizophrenia. Methods Sixty-eight patients with treatment-schizophrenia were randomly assigned to two groups of 34 ones each, research group took orally risperidone plus clozapine and control group did clozapine only for 8 weeks, Efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2na, 4th and 8th week. Results Since the end of the 2nd week, scores of the PANSS of both groups lowered more significantly compared with pretreatment（P〈0. 05）, there were no significant differences in group comparisons（P〉0.05）, at the end of the 8th week, effective rates were respectively 61.76% in the research and 58.82% in the control group, which showed no significant difference（P〉0.05） . Incidences of adverse reactions were respectively 32.35 % in the research and 58.82% in the control group, the former was significantly lower than the latter（P〈0.05） ; adverse reactions were mainly akathisia, tremor and weight gain in the research and sialorrhea, ECG abnormal, dysfunction of liver, leukopenia, drowsiness, dizziness, weight gain and so on in the control group. Conclusion Risperidone combined with clozapine has an evident effect, higher safety and better compliance in the treatment of treatment-resistant schizophrenia.
出处
《临床心身疾病杂志》
CAS
2010年第2期129-131,共3页
Journal of Clinical Psychosomatic Diseases
